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AbstrAct
Objectives To determine the accuracy of the recruitment 
status listed on  ClinicalTrials. gov as compared with the 
actual trial status.
Design Cross-sectional analysis.
setting Random sample of interventional phase 2–4 
clinical trials registered between 2010 and 2012 on  
ClinicalTrials. gov.
Primary outcome measure For each trial which 
was listed within  ClinicalTrials. gov as ongoing, two 
investigators performed a comprehensive literature search 
for evidence that the trial had actually been completed. 
For each trial listed as completed or terminated early by  
ClinicalTrials. gov, we compared the date that the trial was 
actually concluded with the date the registry was updated 
to reflect the study’s conclusion status.
results Among the 405 included trials, 92 had a registry 
status indicating that study activity was either ongoing 
or the recruitment status was unknown. Of these, 
published results were available for 34 (37%). Among the 
313 concluded trials, the median delay between study 
completion and a registry update reflecting that the study 
had ended was 141 days (IQR 48–419), with delays of over 
1 year present for 29%. In total, 125 trials (31%) either had 
a listed recruitment status which was incorrect or had a 
delay of more than 1 year between the time the study was 
concluded and the time the registry recruitment status 
was updated.
conclusions At present, registry recruitment status 
information in  ClinicalTrials. gov is often outdated or 
wrong. This inaccuracy has implications for the ability of 
researchers to identify completed trials and accurately 
characterise all available medical knowledge on a given 
subject.
IntrODuctIOn
Clinical trial registries play an essential role 
in helping to ensure the integrity of the 
published medical literature.1 When used 
appropriately by investigators and sponsors, 
registration helps to ensure that a publicly 
accessible trial record exists even when results 
are not published in a peer-reviewed journal, 
and that published outcome measures are 
consistent with prospectively specified trial 
outcomes. For these reasons, trial registries 
are a particularly important tool for system-
atic reviewers as they attempt to identify 
both published and unpublished trial data in 
order to assess for the possibility of publica-
tion bias.2 
Despite the critical importance of trial 
registration, compliance with require-
ments from both the ICMJE (International 
Committee of Medical Journal Editors) and 
governmental regulators which mandate the 
prospective registration of clinical trials has 
been imperfect.3 4 Meta-researchers have 
begun using data from  ClinicalTrials. gov and 
other registries to identify these patterns of 
limited compliance in order to publicise and 
monitor deficiencies.1 5 6
Within  ClinicalTrials. gov, users have the 
option of using the ‘advanced search’ func-
tion to restrict search results to only those 
trials with a particular recruitment status (ie, 
not yet recruiting, recruiting, completed, and 
so on). Systematic reviewers and meta-re-
searchers often limit registry searches to trials 
for which subject recruitment is documented 
in the registry as having been completed.5 7–13 
Restricting reviews to completed studies makes 
sense because these are the studies for which 
all the data are completed and for which the 
results either are known or could be known. 
However, little is known about delays between 
the time of study completion and the time that 
ClinicalTrials. gov is updated to reflect this 
completion, or the percentage of completed 
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Research
strengths and limitations of this study
 ► Registry recruitment status is often used to identify 
completed clinical trials, yet the reliability of this 
information has not been previously assessed.
 ► The study involved comprehensive, independent 
literature searches by multiple investigators, 
including a medical research librarian.
 ► This study design is unable to identify studies which 
were completed but not published.
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trials which remain listed with an ongoing status in  Clini-
calTrials. gov indefinitely. If these delays are significant or 
a large proportion of registry entries are never updated to 
reflect study completion, then limiting registry searches 
to only entries with a completed registry status might miss 
otherwise relevant trials.
The objective of this study is to quantify delays observed 
between the end of subject recruitment in registered 
clinical trials, and the time that the registry entries are 
updated to reflect that recruitment has ended.
MethODs
study selection and data collection
We searched  ClinicalTrials. gov for phase 2–4 interven-
tional studies registered between 1 January 2010 and 
31 December 2012. From these potentially eligible trials 
(n=30 524) we randomly selected 500 studies for anal-
ysis. Studies with a recruiting status of withdrawn were 
excluded, as this indicates that the study was halted prior 
to enrolling any participants. Trials with a recruiting status 
indicating that recruitment was ongoing and a planned 
primary completion date (date that primary outcome 
data for the final subject are collected) listed within 
ClinicalTrials. gov as being after 1 January 2016 were also 
excluded, as we hypothesised that the yield from a publi-
cation search for trials completed after this date would 
be low. For each included trial, we obtained information 
on study phase, size, sponsor, participant demographics 
and recruitment status as of 1 January 2017 directly from 
ClinicalTrials. gov.
Dates for the following events were also recorded from 
ClinicalTrials. gov for each included trial: initial registra-
tion, study start and primary completion date (date on 
which primary outcome data for the last trial participant 
were collected). When the primary completion date field 
was missing, we used the study completion date (final 
date on which any trial data were collected). We consid-
ered trials with recruitment statuses of either completed 
(study concluded normally) or terminated (recruitment 
stopped prematurely and will not resume) to indicate that 
the study had ended and was unlikely to resume activity. 
These trials were classified as concluded. We recorded the 
dates on which the registry entries were updated to reflect 
that trials had concluded from the History of Changes 
section within each registry entry. Recruiting statuses 
which did not clearly reflect that the trial had concluded 
were recruiting, enrolling by invitation, not yet recruiting, 
active not recruiting, suspended and unknown. Trials 
which were registered more than 1 month after the study 
start date were considered retrospectively registered.
Ongoing or unknown completion status trials
For studies which did not have an updated recruitment 
status indicating that they had concluded, we performed 
a comprehensive literature search to identify published 
evidence that the trial might in fact have been completed. 
An investigator first reviewed the relevant  ClinicalTrials. 
gov entry for relevant publications and searched Medline 
via PubMed using trial registration number, keywords, 
condition studied, intervention, trial title and inves-
tigators’ names for matching manuscripts. When the 
first search identified no corresponding publication, a 
research librarian repeated this search using PubMed, 
Embase and Google Scholar. The final publication search 
occurred between January and February 2017.
We assessed matches between registry entries and 
publications identified by this search strategy using the 
following trial characteristics: study title, trial design, 
interventions, primary and secondary outcomes, number 
of participants, recruitment dates, location and funding 
sources. We did not consider trials to be published if 
the publication did not include outcome data from the 
primary trial. For example, trial protocols for ongoing 
trials were not considered evidence of trial completion. 
We did consider published abstracts and presentations 
at scientific meetings to be evidence of trial completion, 
and counted these as publications for this analysis. For 
the group of included trials with an ongoing or unknown 
recruitment status listed in the registry, the primary 
outcome was the proportion of studies with outcomes 
published in the medical literature.
concluded trials
For studies which were indicated to be concluded based 
on the recruitment status listed in  ClinicalTrials. gov, the 
primary outcome was the amount of time elapsed between 
the primary completion date listed in  ClinicalTrials. gov 
and the date on which the  ClinicalTrials. gov registry entry 
was actually updated to indicate that the study had ended 
and was unlikely to resume activity.
Secondary outcomes included the proportion of studies 
registered more than 1 month after study initiation, and 
the proportion of studies registered after study comple-
tion. We also compared results among subgroups based 
on trial phase, trial size and funding source.
We calculated descriptive data for the primary and 
secondary outcomes. We also compared the median time 
elapsed between the change in recruiting status and the 
time  ClinicalTrials. gov was updated to reflect this change 
between subgroups using Mann-Whitney U test and Krus-
kal-Wallis test. χ2 tests were used to make comparisons 
between categorical variables. p Values <0.05 were consid-
ered statistically significant. Statistical analyses were 
performed using PASW V.18.0 (IBM, Armonk, NY). The 
data set generated during the current study is available 
from the corresponding author on reasonable request.
results
Of the 500 potentially eligible trials which were randomly 
selected for evaluation, 405 were eligible for inclusion 
(figure 1). Phase 2, 3 and 4 trials were all well represented 
within the study sample, and the majority of trials (53%) 
had received at least partial industry funding (table 1). A 
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Figure 1 Flow chart of included trials.
large proportion of trials were registered retrospectively, 
more than 1 month after the study had started (39%).
Out of the 405 included trials, 273 (67%) were listed in 
ClinicalTrials. gov with a study status of completed, and 40 
(10%) had initiated subject recruitment but were termi-
nated early. Ninety-two trials (23%) had a recruitment 
status which indicated that trial activities were ongoing 
or that the study status was unknown, including 22 (5%) 
listed as active or active but not recruiting, and 70 (17%) 
listed as having an unknown recruiting status. Of these 92 
trials with statuses in  ClinicalTrials. gov indicating poten-
tially ongoing study activity, we identified a corresponding 
publication containing outcome data for 34 trials (37%).
Among the trials with a completed or terminated status 
(n=313), two were missing the study completion date. Of 
the remaining 311 trials, the median delay between when 
a trial was completed and when  ClinicalTrials. gov was 
updated to reflect this change was 142 days (IQR 48–419), 
with a mean delay of 340 days. For 127 trials (41%), the 
recruitment status was changed promptly, with a delay of 
less than or equal to 90 days. In 91 trials (29%) this delay 
was greater than 1 year, and in 39 trials (13%) the delay 
was greater than 2 years (figure 2). Eight trials had delays 
of more than 5 years. Retrospectively registered trials had 
a median delay of 266 days (IQR 62–650 days) between 
trial completion and when the registered recruitment 
status was updated, compared with a median of 116 
days (IQR 38–260) for prospectively registered trials 
(p<0.001). Observed delays did not differ between trials 
according to funding source or trial phase.
When considering all 405 included trials, 125 (31%) 
either had a listed recruitment status which was incor-
rect (ie, trial had been completed but was not listed as 
such) or had a delay of more than 1 year between the time 
the study was completed and the time the recruitment 
status was updated. Retrospectively registered trials were 
more likely than prospectively registered trials to have 
one of these major discrepancies in recruitment status, 
with discrepancies observed for 46% of retrospectively 
registered trials and 21% of prospectively registered trials 
(p<0.001). Major recruitment status discrepancies were 
particularly common among those trials registered more 
than 1 year after the onset of recruitment (37/56, 66%). 
Major recruitment status discrepancies were also very 
common among trials which started recruitment before 
2006 (14/15, 93%), though this estimate is based on a 
very small number of trials. Major discrepancies were 
less common, but not unusual among trials which started 
recruitment from 2006 to 2009 (21/37, 57%), from 2010 
to 2011 (59/235, 25%) and from 2012 to 2014 (31/116, 
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Table 1 Characteristics of included trials
Trial characteristics
All trials
(n=405)
Concluded
(n=313)
Potentially ongoing
(n=92)
Number of participants, median (IQR)  80 (32–225) 80 (30–230) 80 (40–173)
Trial phase, n (%)
  Phase 2 186 147 (79) 39 (21)
  Phase 3 or 2/3 132 101 (77) 31 (23)
  Phase 4 87 65 (75) 22 (25)
Funding source, n (%)*
  Industry 214 187 (87) 27 (13)
  NIH/US government 23 17 (74) 6 (26)
  Other 233 155 (67) 78 (33)
Trial start date, n (%)
  Unlisted 2 1 (50) 1 (50)
  Prior to 2006 15 14 (93) 1 (7)
  2006–2009 37 29 (78) 8 (22)
  2010–2011 235 176 (75) 59 (25)
  2012–2014 116 93 (80) 23 (20)
Registered retrospectively, n (%)† 159 124 (78) 35 (22)
Registered prospectively, n (%) 245 189 (77) 56 (23)
Major discrepancy in recruitment status‡ 125 91 (73) 34 (27)
*Trials could have more than one funding source.
†Registration timing relative to recruitment could not be determined for one study.
‡Listed recruitment status within ClinicalTrials.gov was incorrect or there was a delay of more than 1 year between when the study concluded 
and when the registry recruitment status was updated to reflect that recruitment ended.
NIH, National Institutes of Health.
Figure 2 Delays in updating ClinicalTrials.gov following 
trial conclusion. Histogram of completed or terminated 
trials (n=311), depicting delays between the actual date of 
trial conclusion and the date on which ClinicalTrials.gov 
was updated to indicate trial conclusion. Does not show 
eight outliers with delays of greater than 54 months. Trial 
completion dates were also not listed for two trials.
27%). Recruitment status discrepancies did not differ 
among trials based on funding source or trial phase.
DIscussIOn
Among this sample of over 400 phase 2–4 trials registered 
with  ClinicalTrials. gov between 2010 and 2012, we iden-
tified frequent discrepancies between trial recruitment 
statuses listed on  ClinicalTrials. gov and the actual trial 
status. Specifically, 37% of trials which were indicated 
to be ongoing based on available information within 
the registry had been completed and published. Among 
completed trials, 29% had a delay of more than a year 
between trial completion and the  ClinicalTrials. gov 
update reporting trial completion.
Trial registries are an important tool by which both the 
authors of clinical guidelines and systematic reviewers 
can identify relevant clinical trials.2 14 However, in 
both cases authors often assume that the listed recruit-
ment status is accurate and either restrict their registry 
searches to completed trials,7–9 or conclude that those 
trials with active recruitment statuses are actually still 
ongoing.15–19 Our findings show that this assumption 
is incorrect for a substantial portion of trials. Recruit-
ment status discrepancies were particularly common 
among trials registered before 2006 and among retro-
spectively registered trials, which may reflect poor 
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investigator familiarity with registry use in general, 
failure to prioritise correct registry use or changing 
registration patterns over time.
One potential solution to the problem of outdated 
recruitment status information is to not limit registry 
searches to completed trials. For trials which are listed as 
ongoing, efforts should be made to confirm the recruit-
ment status or search for published results regardless of 
the registered recruitment status. In addition to a compre-
hensive search for published results, in some cases these 
efforts should include contacting investigators or study 
sponsors to confirm recruitment status. Given the high 
rate of recruitment status discrepancies observed among 
retrospectively registered trials and trials registered prior 
to 2006, the listed  ClinicalTrials. gov recruitment status 
should be considered particularly unreliable for these 
trials.
Trial registries serve as a critical source of data about 
ongoing and completed trials which supplements the 
published medical literature. However, our findings are 
consistent with previous studies which have demonstrated 
that registry information is at times incomplete or out 
of date.5 20 This work is performed by meta-researchers 
who use registry information to measure compliance 
with trial registration requirements and to monitor the 
conduct and reporting of clinical trials.1 In order to 
accurately perform this function, it is also important for 
meta-researches to recognise the limitations we describe 
with respect to registered trial recruiting statuses. This is 
particularly important for registry-based investigations 
into publication bias, as excluding registered trials with a 
registry status indicating that recruitment is ongoing may 
miss trials which have actually finished enrolment without 
updating the associated registry entry.5 10–13
Several important limitations should be considered 
when interpreting these results. First, our findings are 
based on a sample of phase 2–4 trials registered from 
2010 to 2012; these general results may not be appli-
cable to specific classes of clinical trials, and the patterns 
we observed may change over time. Additionally, we 
performed a literature search to identify trials which were 
listed in the registry as being ongoing, but which had actu-
ally been completed. It is likely that some additional trials 
were completed but not yet published; our search would 
not have identified these trials. Similarly, our literature 
search may have missed some trials. For these reasons, we 
may have underestimated the percentage of trials which 
were completed without updating the registry’s recruit-
ment status.
cOnclusIOns
In summary, we observed that a significant percentage 
of clinical trials registered in  ClinicalTrials. gov with a 
recruitment status indicating that the trial is ongoing have 
actually been completed. Additionally, among completed 
trials, we observed significant delays in updating the 
ClinicalTrials. gov recruitment status. Individuals using 
registry data to supplement a systematic literature search 
and meta-researchers using registry data to study the 
conduct and reporting of clinical trials should be aware 
of these findings to avoid unwarranted assumptions about 
the recruitment status of registered trials.
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